Grant: CIHR Fellowship
University of Toronto
$165,000.00
Biomarkers of heart failure in adults with congenital heart disease: towards personalized medicine
EF 2009-10
Résumé
With advances in surgical and procedural techniques, cardioprotection, and perioperative care in recent decades, increasing numbers of patients with congenital heart disease are surviving to adulthood. Many patients with congenital heart disease unfortunately develop heart failure, which is characterized by the inability of the heart to meet the body's demand for oxygen and nutrients. They can also have a reduced exercise tolerance and become short of breath with exercise. Studies have shown that these patients have a high mortality rate as well as poor quality of life. So far, there is no unified way to diagnose heart failure in adults with congenital heart disease, especially at an early stage. There is also no proven treatment for this disease.
The goal of this project is to discover biomarkers which can help diagnose heart failure in this unique complex and growing population of patients with congenital heart disease. This will allow us to understand the unique pathways that lead to heart failure in this patient population. Understanding this disease is the first step toward developing personalized diagnostic methods and treatments for patients with congenital heart disease and heart failure. We will use two approaches to discover congenital heart disease and heart failure biomarkers. In the systems biology approach, we will search for key targets. Microarray technology will enable us to measure the activity of tens of thousands of genes simultaneously. We plan to compare gene expression of healthy individuals to those with different groups of congenital heart defects with heart failure using microarray analysis. This will allow us to find unique changes in gene expression and ultimately biological pathways related to heart failure in this adult population. Our second approach is candidate gene approach. From work previously done in our laboratory, there are a few targets that we suspect are important for heart failure in adults with congenital heart disease.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206459
Name
Piran Sanaz
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Biomarkers of heart failure in adults with congenital heart disease: towards personalized medicine
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$165,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biomarkers; Congenital Heart Disease; Genomics; Heart Failure; Microarray; Proteomics
Abstract
With advances in surgical and procedural techniques, cardioprotection, and perioperative care in recent decades, increasing numbers of patients with congenital heart disease are surviving to adulthood. Many patients with congenital heart disease unfortunately develop heart failure, which is characterized by the inability of the heart to meet the body's demand for oxygen and nutrients. They can also have a reduced exercise tolerance and become short of breath with exercise. Studies have shown that these patients have a high mortality rate as well as poor quality of life. So far, there is no unified way to diagnose heart failure in adults with congenital heart disease, especially at an early stage. There is also no proven treatment for this disease.
The goal of this project is to discover biomarkers which can help diagnose heart failure in this unique complex and growing population of patients with congenital heart disease. This will allow us to understand the unique pathways that lead to heart failure in this patient population. Understanding this disease is the first step toward developing personalized diagnostic methods and treatments for patients with congenital heart disease and heart failure. We will use two approaches to discover congenital heart disease and heart failure biomarkers. In the systems biology approach, we will search for key targets. Microarray technology will enable us to measure the activity of tens of thousands of genes simultaneously. We plan to compare gene expression of healthy individuals to those with different groups of congenital heart defects with heart failure using microarray analysis. This will allow us to find unique changes in gene expression and ultimately biological pathways related to heart failure in this adult population. Our second approach is candidate gene approach. From work previously done in our laboratory, there are a few targets that we suspect are important for heart failure in adults with congenital heart disease.
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Piran, Sanaz
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $165,000~ $0~